

FIG. 1A

ID Interna		CDR1	CDR2	CDR3
312557	SEQ ID NO:1	GFTFDDYA	ISWNSGSI	AKDSRGYGDYRLGGAY
308261	SEQ ID NO:2	GFTFDDYA	ISWNSGSI	AKDSRGYGDYRLGGAY
308159	SEQ ID NO:3	GFTFDDYA	ISWNSGSI	AKDSRGYGDYSRGGAY
308160	SEQ ID NO:4	GFTFDDYA	ISWNSGSI	AKDSRGYGDYSLGGAY
308256	SEQ ID NO:5	GFTFDDYA	ISWNSGSI	AKDSRGYGDYSLGGAY
312585	SEQ ID NO:6	GFTFANYA	ISWNSGSI	AKDSRGYGDYSRGGAY
312614	SEQ ID NO:7	GFTFNNTA	ISWNSGSI	AKDSRGYGDYSRGGAY
312583	SEQ ID NO:8	GFTFADYA	ISWNSGSI	AKDSRGYGDYSRGGAY
312586	SEQ ID NO:9	GFTFDNTA	ISWNSGSI	AKDSRGYGDYSRGGAY
312624	SEQ ID NO:10	GFTFDNTA	ISWNSGSI	AKDSRGYGDYSRGGAY
312578	SEQ ID NO:11	GFTFDDYA	ISWNSGSI	AKDSRGYGDYSRGGAY
312620	SEQ ID NO:12	GFTFDDYA	ISWNSGSI	AKDSRGYGSYSRGGAY
312634	SEQ ID NO:13	GFTFHNTA	ISWNSGSI	AKDSRGYGDYSLGGAY
312579	SEQ ID NO:14	GFTFDDYA	ISWNSGSI	AKDSRGYGDYSRGGAY
312630	SEQ ID NO:15	GFTFDNTA	ISWNSGSI	AKDSRGYGDYSLGGAY
312570	SEQ ID NO:16	GFTFDDYA	ISWNSGSI	AKDSRGYGDYRLGGAY
312567	SEQ ID NO:17	GFTFDDYA	ISWNSGSI	AKDSRGYGDYRLGGAY
312558	SEQ ID NO:18	GFTFDDYA	ISWNSGSI	AKDSRGYGDYRLGGAY

FIG. 1B

312325	SEQ ID NO:19	QSVSSN	GAS	QQYNNWPWT
308902-bivalente	SEQ ID NO:20	GFTVSSYG	IRGSDGST	AKQGENDGPFDH
308902	SREQ ID NO:21	GFTVSSYG	IRGSDGST	AKQGENDGPFDH

FIG. 1C

304703	SEQ ID NO. 22	GGSISSGGHY	IHYSGST	ARWRHDIFAAYPYYYGMDV
--------	---------------	------------	---------	---------------------

anti-CD3 antígeno
 antitumoral




FIG. 2A

anti-CD3 antígeno
 antitumoral




FIG. 2B

anti-CD3 antígeno
 antitumoral




FIG. 2C

anti-CD3 **antígeno
antitumoral**




FIG. 2D

**antígeno
antitumoral** **anti-CD3**




FIG. 2E

Columna

1 2 3 4 5 6 7 8 9 10 11 12 13

ANTICUERPO ANTI-CD3 ORIGINAL			ANTICUERPO BIESPECÍFICO ANTI-CD3:ANTI-BCMA									
ID de anti-CD3	unión células Jurkat (MFI)	unión linfocitos T cymo (MFI)	con dosis de B ₂ Ab en ng/mL	IL-2	IL-6	IL-10	IFN γ	TNF α	EC50 dest. (ng/mL)	% de dest. (333ng/mL)	KD (nM)	unión células Jurkat (MFI)
312624	30.5	1.4	CD3_F2E-BCMA	130	1.0	24.1	705	1787	2.0	63	227	296
312585	32.7	0.9	CD3_F2C-BCMA	93	0.5	19.2	751	1821	2.1	68	44	513
312614	32.4	0.9	CD3_F2D-BCMA	294	1.5	89.9	1185	2387	6.1	63	86	357
312634	21.4	1.1	CD3_F2F-BCMA	44	0.5	2.4	333	485	9.8	51	714	67
312608	25.9	1.0	CD3_F2A-BCMA	96	0.5	3.3	505	1161	22.2	59	199	110
312557	6.1	1.0	CD3_F2B-BCMA	8	0.5	0.6	154	553	150.1	38	1000	31
312568	4.1	1.2	CD3_F2G-BCMA	1	0.5	0.5	29	231	352.0	12	ND	9
304703	15.9	26.2	CD3_F1A-BCMA	212	0.8	48.5	726	1844	6.4	71	98	149

FIG. 3

FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8A

RPMI-8226




FIG. 8B

NCI-H929




FIG. 8C

U-266




FIG. 8D

K562




FIG. 9A RPMI-8226




FIG. 9B NCI-H929




FIG. 9C U-266




FIG. 9D K562




FIG. 10A

RPMI-8226




FIG. 10B

NCI-H929




FIG. 10C

U-266




FIG. 10D

K562

